**WHO Endorses Single‑Dose RSV Vaccine for Over‑60s After Two‑Year Trial Shows 78% Efficacy**
The World Health Organization has endorsed a single‑dose respiratory syncytial virus (RSV) vaccine for adults aged 60 and over, following a two‑year clinical trial demonstrating **78% efficacy** in preventing symptomatic RSV disease. The recommendation signals a major stride in protecting one of the most vulnerable and often overlooked populations worldwide — older adults with age‑related immune decline and chronic comorbidities.
The two‑year trial data reviewed by WHO panels showed consistent protection across diverse geographic settings and participant subgroups, prompting experts to weigh the vaccine’s potential to reduce hospitalizations, complications, and excess mortality during seasonal RSV waves. **Single‑dose administration** emerged as a practical advantage: it simplifies delivery, accelerates population coverage, and reduces logistical burdens for national immunization programs, particularly in low‑ and middle‑income countries (LMICs).
Why this matters globally
RSV is widely known for severe disease in infants, but its burden among older adults is substantial and underrecognized. In aging populations, RSV precipitates exacerbations of heart and lung disease and contributes to hospital admissions and long‑term functional decline. **A vaccine with robust efficacy for seniors could shift the public health calculus**, reducing strain on health systems during concurrent respiratory seasons and complementing influenza and COVID‑19 mitigation strategies.
Equity and implementation challenges
WHO’s endorsement sets the tone for procurement, financing, and roll‑out — but major hurdles remain. **Equitable access** will depend on manufacturing scale‑up, price negotiations, and integration into existing adult vaccination platforms. Stakeholders such as Gavi, UNICEF, regional procurement mechanisms, and national immunization programs will be pivotal in translating endorsement into coverage. The single‑dose profile helps, but cold‑chain capacity, trained workforce, and community engagement are essential to reach frail and homebound seniors.
Safety, surveillance, and co‑administration
Safety signals in the trial were acceptable across age groups, though WHO emphasized the need for continued post‑deployment monitoring. Pharmacovigilance systems must be strengthened globally to detect rare adverse events and to assess effectiveness against evolving RSV strains. **Questions about co‑administration with influenza and COVID‑19 vaccines** remain operationally important; coordinated scheduling could improve uptake but requires clear guidance grounded in immunological and safety data.
Policy implications and the path forward
National health authorities will now weigh WHO’s endorsement against local epidemiology and budgetary constraints. For countries with aging populations and high RSV burden, adopting the vaccine may be cost‑effective by preventing hospitalizations and preserving healthcare capacity. For LMICs, donor support and tiered pricing will likely determine rollout speed. Research priorities include duration of protection in the very old, vaccine performance against different RSV subtypes, and development of combination adult respiratory vaccines.
Conclusion — strategic opportunity ahead
WHO’s endorsement of a single‑dose RSV vaccine for over‑60s represents a pivotal moment in adult immunization policy. **If deployed equitably and paired with vigilant surveillance, the vaccine could substantially reduce RSV’s global toll among seniors.** The next 12–24 months will be critical: manufacturers, funders, and national programs must align to translate trial efficacy into real‑world impact, while scientists continue to refine strategies for long‑term protection and broader respiratory disease control.
